Raymond Kaempfer
Corporate Officer/Principal bei European Molecular Biology Organization
Aktive Positionen von Raymond Kaempfer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| European Molecular Biology Organization | Corporate Officer/Principal | - | - |
Karriereverlauf von Raymond Kaempfer
Ehemalige bekannte Positionen von Raymond Kaempfer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Direktor/Vorstandsmitglied | 01.01.2003 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | - | |
| Gründer | 01.01.2003 | - |
Ausbildung von Raymond Kaempfer
| Massachusetts Institute of Technology | Doctorate Degree |
Statistik
International
| Israel | 3 |
| Vereinigte Staaten | 3 |
| Deutschland | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
| European Molecular Biology Organization |
- Börse
- Insiders
- Raymond Kaempfer
- Erfahrung
